Avalo Therapeutics, Inc.
AVTX· Nasdaq
Released Nov 7, 2024, before the open
10-Q filed Nov 7, 2024, 38 days after period end · 0001628280-24-045965
| Metric | Q3 2024 | Q3 2023 | Q3 2022 | Q3 2021 |
|---|---|---|---|---|
| Revenue | $249.00K | $236.00K | $14.95M | $1.35M |
| Net Income | $23.04M | -$5.23M | $3.19M | -$17.40M |
| EPS Diluted |
Avalo Therapeutics, Inc. · CIK 1534120 · Engraved from SEC EDGAR
| -$2.83 |
| -$26.83 |
| $0.34 |
| — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.